The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

One in three women will become pregnant after an MS diagnosis, therefore consideration of the maternal-infant dyad is needed.

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

MS is a disease of the nervous system. Many nerves have a myelin sheath — a protective layer that wraps around them and ...

2025 Healthcare & Pharmaceuticalscategory Roche fails in bid to increase dose of MS drug Ocrevus April 2, 2025 Healthcare & Pharmaceuticalscategory US Supreme Court largely backs FDA's denial of ...

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain ...